November 23, 2016 - By Dolores Ford
N+1 Singer currently has a GBX 208.00 target price per share on the 1.02B GBP market cap company or 38.34% upside potential. In a research note revealed to investors on 23 November, Vectura Group PLC (LON:VEC) stock had its “Buy” Rating reiterated by investment analysts at N+1 Singer.
Out of 8 analysts covering Vectura Group PLC (LON:VEC), 7 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 88% are positive. GBX 279 is the highest target while GBX 160 is the lowest. The GBX 215.25 average target is 43.21% above today’s (GBX 150.3) stock price. Vectura Group PLC has been the topic of 58 analyst reports since July 28, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Monday, January 4 by N+1 Singer. The rating was maintained by JP Morgan with “Overweight” on Monday, November 2. The firm earned “Overweight” rating on Wednesday, November 18 by JP Morgan. The rating was maintained by FinnCap on Tuesday, November 17 with “Buy”. The firm has “Buy” rating given on Monday, September 19 by Numis Securities. The company was maintained on Friday, July 29 by Stifel Nicolaus. As per Tuesday, November 17, the company rating was maintained by N+1 Singer. The firm has “Buy” rating by Numis Securities given on Thursday, May 26. Numis Securities maintained Vectura Group PLC (LON:VEC) rating on Tuesday, August 30. Numis Securities has “Buy” rating and GBX 246 price target. Stifel Nicolaus maintained the shares of VEC in a report on Thursday, May 26 with “Buy” rating.
About 2.08M shares traded hands or 20.93% up from the average. Vectura Group PLC (LON:VEC) has declined 16.40% since April 22, 2016 and is downtrending. It has underperformed by 21.73% the S&P500.
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The company has a market cap of 1.02 billion GBP. The Company’s products include Ultibro Breezhaler and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA. It has a 131.5 P/E ratio. The Company’s product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465.
According to Zacks Investment Research, “Vectrus, Inc. engages in providing infrastructure asset management, logistics and supply chain management, and information technology and network communication services. Its services include operations, maintenance, management, engineering and sustainment for physical assets including a wide variety of facilities, information technology, network and communication systems, vehicles and equipment. The Company serves U.S. government customers worldwide. Vectrus, Inc. is based in United States.”
Vectrus, Inc., incorporated on February 4, 2014, is a well-known provider of services to the United States Government across the world. The Firm offers services, including infrastructure asset management, logistics and supply chain management, and information technology and network communication. The Company’s infrastructure asset management services support the United States Army, Air Force and Navy, and include infrastructure services, security, warehouse management and distribution, ammunition management, civil engineering, air base maintenance and operations, communications, emergency services, transportation, and life support activities at various global military installations. The Company’s logistics and supply chain management services support and maintain the vehicle and equipment stocks of the United States Army and Marine Corps. The Company’s information technology and network communication services consist of sustainment of communications systems, network security, systems installation and full life cycle management of information technology systems. The Firm provides global service solutions in over 130 locations and approximately 20 countries across over three continents.
More news for Vectura Group PLC (LON:VEC) were recently published by: Fool.Co.Uk, which released: “Why Vectura group plc and GlaxoSmithKline plc could be the perfect combination” on September 07, 2016. Rttnews.com‘s article titled: “Vectura Group Signs with Hikma for Development of Asthma and COPD Product” and published on November 22, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Dolores Ford